NDA 019851 · Validus Pharms
Lotensin
Benazepril Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jan 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jun 25, 1991
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
53
7 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Benazepril" as an intervention, any sponsor and status, largest first.
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Standard Medical Management in Secondary Prevention of Ischemic Stroke in ChinaPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT00664846 · 4,000 participants (planned) · Start Apr 2008 · Primary completion Dec 2010
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Asprin / Clopidogrel, Atorvastatin / Simvastatin · For: Stroke
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 46 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171366 · 1,422 participants · Start Jul 2004 · Primary completion Jul 2005
Drug: amlodipine/benazepril · For: Hypertension
Sites: East Hanover, New Jersey
- Preventing Microalbuminuria in Type 2 DiabetesPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT00503152 · 612 participants · Start May 2007 · Primary completion Jul 2016
Drug: Benazepril; Valsartan and 1 more · For: Diabetes
Sites: Ponte San Pietro, Italy; Ranica, Italy; Romano di Lombardia, Italy · 9 sites in all
- ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)Pivotal-lookingCompleted
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT03682692 · 560 participants · Start Jun 1, 2018 · Primary completion Jun 30, 2021
Drug: ACEI/CCB; ACEI/DIU · For: Hypertension
Sites: Shanghai, China
- Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep TreatmentPivotal-lookingStatus unknown
Henan University of Traditional Chinese MedicineAcademic, hospital or other
NCT03591471 · 500 participants (planned) · Start Sep 2014 · Primary completion Dec 2018
Drug: Glycosides Of Tripterygium Wilfordii Hook(GTW); Sulfotanshinone Sodium Injection and 6 more · For: Henoch-Schönlein Purpura Nephritis
Sites: Zhengzhou, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
Hu Y, Liang L, Liu S, et al. · J Clin Hypertens (Greenwich) 2023 · Systematic Review, Network Meta-Analysis
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K, Weber MA, Bakris GL, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- [Effects of lotensin and nitrendipine on plasma fibrinogen and platelet aggregation in hypertensive patients].
Pan R, Sun M, Zhou H, et al. · Hunan Yi Ke Da Xue Xue Bao 1998 · Clinical Trial, English Abstract
- Effect of azilsartan on myocardial remodeling after acute myocardial infarction.
Wang J, Ding Y, Yao YR, et al. · Eur J Clin Pharmacol 2024 · Randomized Controlled Trial
- [Effect of Baoyuan Qiangshen capsule no. II on tubular interstitial injury in chronic renal failure patients].
Zhu P, Wei X, Zhao W · Zhongguo Zhong Xi Yi Jie He Za Zhi 1999 · Clinical Trial, English Abstract
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.